Partnership aims to create an end-to-end supply chain that will enable the developers of these treatments to meet increasing global demand
Photo as seen on company website
GE Healthcare and World Courier are combining their expertise in manufacturing and logistics to better patient access to cell and gene therapies. Together, they aim to create a seamless end-to-end supply chain that will enable the developers of these treatments to meet increasing global demand. This collaboration is designed to support the commercialisation of advanced therapies.
By leveraging the manufacturing efficiencies of GE Healthcare’s FlexFactory, a semi-automated, modular end-to-end manufacturing platform, and World Courier’s robust global logistics platform, drug manufacturers will be able to deliver life-altering therapies that have time- and temperature- critical conditions globally.
Catarina Flyborg, General Manager, Cell and Gene Therapy, GE Healthcare, said: “As GE Healthcare works to advance the development of cell and gene therapies, it is critical that we offer our customers agile solutions that can help them meet global demand. By working with World Courier and leveraging their robust logistics platform and global infrastructure, we are providing a solution that will spur commercialisation and access to next-generation therapeutics.”
With more than 900 regenerative medicine companies and more than 1,000 clinical trials underway worldwide in 2018, the industry is growing at an exponential pace. Creating robust supply chains that can efficiently scale up and connect the right therapies to the right patient is key to enabling the commercialisation of cell and gene therapies.
Sam Herbert, President of World Courier, explained: “We’ve developed a proprietary network and global footprint that meets the constantly evolving shipping requirements and complex therapeutics of today.”